Question special
Moderator

Obviously a cost analysis study would need to be done separately from an efficacy study, but how do you anticipate costs to compare between cffDNA and 1st trimester screening, or cffDNA and 1st+2nd trimester screening? Would a switch in screening methods be feasible only in major medical centers, or fairly widely available?